Andrew Rudd is the co-founder of Palm Therapeutics and co-inventor of DPALM technology. He performed his PhD work in the Devaraj Lab at UCSD where he developed the first small molecule approach for protein depalmitoylation. During his PhD, Andrew authored several high-impact papers and received notable awards for his scientific achievement including the Inamori Fellowship.
Neal Devaraj, co-founder of Palm, is a Professor of Chemistry and Biochemistry at the University of California, San Diego (UCSD) and co-inventor of DPALM technology. He earned his PhD in Chemistry at Stanford University in the labs of Profs. James Collman and Christopher Chidsey. After a postdoctoral fellowship at the Harvard Medical School in the lab of Prof. Ralph Weissleder, he joined UCSD. He is a world leader in bioconjugation, chemical biology, and bottom-up synthetic biology. His work has been recognized by the prestigious ACS Award in Pure Chemistry and he was recently named the 2018 Blavatnik National Laureate in Chemistry.
Peter Chu is a scientist-turned-entrepreneur, biotech executive and investor who has spent the last 15+ years on both the research and executive management side of small, medium and large biotech companies. He was the founding CEO of Eclipse Therapeutics, a Biogen Idec (NASDAQ:BIIB) spinout that was acquired by Bionomics Ltd (BNO:ASX), where he led development of the cancer stem cell antibody BNC101 from conception through to human clinical trials in colon cancer. He is an active member of the San Diego Tech Coast Angels and a board director at Echo Laboratories.
Copyright © 2018-2020 Palm Therapeutics - All Rights Reserved.